Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics' Q1 Revenues Rise 8 Percent

NEW YORK (GenomeWeb News) – Strategic Diagnostics yesterday reported first-quarter revenue growth of 8 percent and swung from a profit to a slight loss.
 
For the three-month period ended March 31, the Newark, Del.-based firm reported revenues of $7.2 million, up from $6.6 million in the first quarter of 2007. The firm said that primary growth drivers for the quarter were its food pathogen product sales, which climbed 36 percent year over year, and its antibody products, which increased 15 percent.
 
Strategic Diagnostics posted a net loss of $12,000, or $.00 per share, versus a profit of $490,000, or $.02 per share, for the first quarter of 2007.
 
The firm’s R&D expenses rose 35 percent to $940,000 from $697,000 year over year, while its SG&A costs increased 18.5 percent to $3.2 million from $2.7 million.
 
Strategic Diagnostics finished the quarter with $12.5 million in cash and cash equivalents.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.